All In Biotech

Drug Trial Radar · NCT00471705

Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.

Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.

Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

437

Actual

Start

Jun 2006

Primary completion

Aug 2008

Study completion Dec 2009

Sponsor

Lead sponsor
Universidad de AntioquiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dirección de Sanidad del Ejército de Colombia (DISAN); Ministerio de Salud y Protección Social, Colombia
First posted
May 10, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cutaneous leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence the last two decades. It is estimated that in 2005, about of 20,000 new cases of CL were diagnosed in Colombia. So far, pentavalent antimony compounds have been considered the treatment of choice with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their adverse events and disadvantages. Previous studies have shown that miltefosine could be a potential alternative of treatment for CL. The main objective of this study is to evaluate the efficacy and safety of miltefosine or thermotherapy for the treatment for CL. In this study the efficacy of oral treatment of miltefosine 150 mg/day for 28 days or a thermotherapy device used for one session at 50 celsius degrees during 30 seconds will be compared with the standard treatment of intramuscular injections of 20 mg/Kg/day of pentavalent antimonials (GlucantimeÒ) for 20 days in CL parasitologically proven patients. This trial will be conducted according to the International approved GCP (Good Clinical Practice) guidelines.

Conditions

  • Cutaneous Leishmaniasis

Interventions

  • MiltefosineDrug

    Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.

  • ThermotherapyDevice

    One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.

  • Glucantime®Drug

    Glucantime® 20 mg /Kg /day for 20 days (intramuscular)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Clinical ResponseTime frame: Until 6 months posttreatment
  2. FailureTime frame: Until 3 months posttreatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Program for Research and Control in Tropical Diseases - PECET

    Medellín, Antioquia, Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.